TendoGuard Study Yields Positive Initial Results

MURRIETA, Calif.Certified Nutraceuticals announced positive initial results of its ongoing human clinical study examining the efficacy of its TendoGuard ingredient. The trial is being performed by Morton Scientific Group, Cambridge, Ontario, and includes 15 patients (ages 17 to 81 years) with confirmed joint damage and cartilage injury. Dosage is 1,500 mg/d to 2,500 mg/d as dietary supplement taken with citric juice on an empty stomach.

Supplementation with TendoGuard produced a significant treatment response at seven days for flexibility (29.6% increase, P=0.036) and at 30 days for general pain (84.1% reduction, P=0.006), flexibility (45.5% increase, P=0.005) and range of motion associated pain (74.7% reduction, P=0.020). Further, after 30 days of supplementation, participants' salivary pH had normalized; generally, during an inflammatory state in the body, the pH of saliva drops considerably as a secondary response. Participants also reported positive responses in skin condition and mobility.

The ingredient is covered under U.S. Patent No. 8,344,106 B1, "Collagen Type I, II, V, X isolated from 100% Avian Eggshell Membrane and Sternum Cartilage." It is produced using a proprietary water extraction technology without the use of solvent or harsh chemicals. The ingredient can be incorporated into dietary supplements, foods, beverages and cosmetic applications.